Treatment of Hypertensive Heart Disease by Targeting Smad3 Signaling in Mice
Authors:
- Jinxiu MengJMJinxiu Meng
- Yuyan QinYQYuyan Qin
- Junzhe ChenJCJunzhe Chen
- Lihua WeiLWLihua Wei
- Xiao-Ru HuangXHXiao-Ru Huang
- Xiyong YuXYXiyong Yu
- Hui-Yao LanHLHui-Yao Lan
Open Access
- 1 September 2020
- journal article
- research article
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 18, 791-802
Abstract
No abstract availableKeywords
Funding Information
- Research Grants Council, University Grants Committee
This publication has 35 references indexed in Scilit:
- TGF-β: the master regulator of fibrosisNature Reviews Nephrology, 2016
- The Burden of Hypertension and Associated Risk for Cardiovascular Mortality in ChinaJAMA Internal Medicine, 2016
- Alterations in Cardiac Structure and Function in HypertensionCurrent Hypertension Reports, 2014
- New Take on the Role of Angiotensin II in Cardiac Hypertrophy and FibrosisHypertension, 2011
- Angiotensin II Induces Connective Tissue Growth Factor and Collagen I Expression via Transforming Growth Factor–β–Dependent and –Independent Smad PathwaysHypertension, 2009
- Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular systemAmerican Journal of Physiology-Cell Physiology, 2007
- Essential Role of Smad3 in Angiotensin II–Induced Vascular FibrosisCirculation Research, 2006
- Angiotensin II Activates the Smad Pathway in Vascular Smooth Muscle Cells by a Transforming Growth Factor-β–Independent MechanismCirculation, 2005
- Left Ventricular Concentric Geometry During Treatment Adversely Affects Cardiovascular Prognosis in Hypertensive PatientsHypertension, 2004
- Stimulation of Type I Collagen Transcription in Human Skin Fibroblasts by TGF-β: Involvement of Smad 3Journal of Investigative Dermatology, 1999